Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ
Condition(s):Atypical Hyperplasia; Lobular Carcinoma in SituLast Updated:October 8, 2020Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Atypical Hyperplasia; Lobular Carcinoma in SituLast Updated:October 8, 2020Not yet recruiting
Condition(s):Breast CancerLast Updated:August 12, 2013Unknown status
Condition(s):Breast Cancer; Lobular Carcinoma; Invasive Breast CancerLast Updated:November 6, 2020Active, not recruiting
Condition(s):Atypical Lobular Hyperplasia; Atypical Ductal Hyperplasia; Lobular Carcinoma in SituLast Updated:October 10, 2016Completed
Condition(s):Atypical Hyperplasia of the Breast; Lobular Breast Carcinoma In Situ; Pleomorphic Lobular Breast Carcinoma In SituLast Updated:January 7, 2021Recruiting
Condition(s):Breast CancerLast Updated:December 26, 2019Completed
Condition(s):Intraductal Carcinoma and Lobular Carcinoma in SituLast Updated:August 25, 2016Completed
Condition(s):Atypical Ductal Breast Hyperplasia; Lobular Carcinoma in Situ (LCIS); Atypical Lobular Hyperplasia (ALH) of BreastLast Updated:December 5, 2016Completed
Condition(s):Breast CancerLast Updated:April 8, 2020Active, not recruiting
Condition(s):Breast NeoplasmsLast Updated:March 31, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.